BCYC
Bicycle Therapeutics plcNASDAQHealthcare$5.05+3.06%ClosedMarket Cap: $349.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.56
P/S
4.67
EV/EBITDA
1.16
DCF Value
$-100.47
FCF Yield
-73.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-125.1%
Operating Margin
-340.3%
Net Margin
-301.7%
ROE
-33.2%
ROA
-30.5%
ROIC
-37.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $48.0M | 26.9% | $-24.7M | $-20.2M | $-0.29 | — |
| FY 2025 | $72.6M | 100.0% | $-247.1M | $-219.0M | $-3.16 | — |
| Q3 2025 | $11.7M | 100.0% | $-65.6M | $-59.1M | $-0.85 | — |
| Q2 2025 | $2.9M | -2332.5% | $-86.6M | $-79.0M | $-1.14 | — |
| Q1 2025 | $10.0M | -474.0% | $-70.2M | $-60.8M | $-0.88 | — |
| Q4 2024 | $3.7M | -1412.2% | $-67.7M | $-51.9M | $-0.74 | — |
| FY 2024 | $35.3M | -390.3% | $-209.9M | $-169.0M | $-2.90 | — |
| Q3 2024 | $2.7M | -1605.8% | $-63.8M | $-50.8M | $-0.74 | — |
| Q2 2024 | $9.4M | 100.0% | $-46.6M | $-39.8M | $-0.77 | — |
| Q1 2024 | $19.5M | 100.0% | $-31.7M | $-26.6M | $-0.62 | — |
| Q4 2023 | $5.3M | 100.0% | $-54.2M | $-49.1M | $-1.16 | — |
| FY 2023 | $27.0M | -480.1% | $-189.9M | $-180.7M | $-5.08 | — |